Context Therapeutics Announces First Patient Dosed In Phase 1 Trial Of Nectin-4 x CD3 Bispecific CT-202 In Urothelial, Colorectal, And Triple-Negative Breast Cancers; Says Initial Phase 1a Data Expected In H2 2027
Share
Why It Matters
Context Therapeutics just gave its first patient a new cancer medicine in an early study to see if it works and is safe. This is an early step, so we should watch for their progress reports next year to learn whether the medicine looks promising.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.